SCHEDULE: State Street Discloses 4.6% Stake in Arrowhead Pharma

State Street Corporation has reported a 4.6% beneficial ownership stake in Arrowhead Pharmaceuticals Inc., holding over 6.3 million common shares.

Summary

• State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G indicating beneficial ownership in Arrowhead Pharmaceuticals Inc.
• The filing reports an aggregate beneficial ownership of 6,371,056 shares of Arrowhead Pharmaceuticals Inc. common stock.
• This represents 4.6% of the class of securities.
• State Street Corporation holds shared voting power over 5,952,902 shares and shared dispositive power over 6,371,056 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Subsidiaries identified as acquiring the securities include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, State Street Global Advisors, Australia, Limited, and State Street Global Advisors, Ltd.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G) by a large institutional investor, indicating a passive stake. It does not contain information that would typically alter sentiment positively or negatively regarding the issuer's operational performance or strategic direction.

Future Outlook

NA

Industry Context

This filing is a routine disclosure by a large institutional asset manager, State Street Corporation, indicating a passive investment in Arrowhead Pharmaceuticals Inc. It reflects a standard portfolio holding rather than a strategic industry move or competitive positioning.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, confirming State Street Corporation's passive investment approach.

Key Dates

Keywords

Arrowhead Pharmaceuticals, State Street Corporation, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Holding, Financial Disclosure